



UNITED STATES PATENT AND TRADEMARK OFFICE

CL  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,899	03/23/2004	Steven Petrou	1386/19	2461
25297	7590	11/29/2006	EXAMINER	
JENKINS, WILSON, TAYLOR & HUNT, P. A. 3100 TOWER BLVD SUITE 1200 DURHAM, NC 27707				KAPUSHOC, STEPHEN THOMAS
ART UNIT		PAPER NUMBER		
		1634		

DATE MAILED: 11/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/806,899	PETROU ET AL.
	Examiner Stephen Kapushoc	Art Unit 1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 28 September 2006.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-23 is/are pending in the application.  
 4a) Of the above claim(s) 18, 19, 22 and 23 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-17, 20 and 21 is/are rejected.  
 7) Claim(s) 1-17, 20 and 21 is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 23 March 2004 is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date 4/26/04; 6/28/04; 9/11/06.

4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date. \_\_\_\_\_.  
 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

## DETAILED ACTION

Claims 1-23 are pending.

Claims 18, 19, 22 and 23 are withdrawn.

Claims 1-17, 20, and 21 are examined on the merits.

### *Election/Restrictions*

1. Applicant's election with traverse of the invention of Group I, drawn to nucleic acid based methods for the diagnosis of SMEI in the reply filed on 09/28/2006 is acknowledged. The traversal is on the ground(s) that it would not be burdensome to search the subject matter of Groups III and IV because the claims of Groups III and IV are drawn to correlating a diagnosis of SMEI with appropriate treatment for SMEI patients based on indications and contraindications (Group III) or determining the likelihood of adverse results from treatments (Group IV). This is not found persuasive because Groups III and IV require correlating different diagnoses (e.g. high probability or low probability of SMEI) made by detection of particular different SCNA1 mutations (known, *de novo*, inherited) with treatments (Group III) or adverse result likelihood (Group IV). Thus it appears that the examination of the claims of Groups III and IV require an analysis of the correlation of different mutations with different treatments and adverse event likelihood, where such a search is beyond the scope of the claims of Group I, which requires using the detection of SCNA1 mutations to make a diagnosis of SMEI.

The requirement is still deemed proper and is therefore made FINAL.

Claims 18, 19, 22, and 23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 09/28/2006.

***Priority***

2. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Australia on 03/27/2006. It is noted, however, that applicant has not filed a certified copy of the 2003901425 application as required by 35 U.S.C. 119(b).

***Information Disclosure Statement***

3. The listing of references in the specification is not a proper information disclosure statement; see for example p[ages 47-49 of the specification. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

***Specification***

4. The disclosure is objected to because of the following informalities:  
Table 1 of the specification contains the sequences of forward and reverse primers where the sequences are not accompanied by any SEQ ID NO sequence

identifiers. Accordingly, the specification fails to comply with 37 CFR 1.821(d), which requires the use of the assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences.

Appropriate correction is required.

### ***Sequence Compliance***

5. This application, 10/806,899, contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below:

The application contains sequences that are not identified by SEQ ID NOs and are not contained in the sequence listing of the application. For example, Table 1 (p.44 of the specification) contains nucleic acid sequences of forward and reverse primers that are not identified by a SEQ ID NOs in either the Table or the text of the specification and are not part of the sequence listing of the application.

In order to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), Applicant must submit, as appropriate, a new CRF and paper copy of the Sequence Listing containing the sequences, in addition to the previously listed sequences, an amendment directing the entry of the Sequence Listing into the specification, and a letter stating that the content of the paper and computer readable copies are the same. The specification should also be amended to include the appropriate SEQ ID NOs: in Table 1.

### ***Claim Objections***

6. Claims 1-17, and 20 are objected to because part (3) of claim 1 recites steps indicated as (a), (b), and (d), however there is no step (c). The text of claim 1 should be amended such that alphabetically indicated steps are listed without gaps.

Claims 1-17, and 20 are objected to because part (3)(d) of claim 1 recites 'or, if not known to be either', where the word 'or' may be removed.

Claims 4 and 21 are objected to because they specifically recite non-elected subject matter. Claims 4 and 21 recite methods requiring the use of SCN1A alterations as presented in Table 3. In response to the requirement for restriction Applicant has elected for the examination of the claims in so far as they require the c251A→G nucleotide change. Prior to allowance of these claims, the non-elected subject matter will be required to be deleted from the claims.

Claim 21 is objected to because the claim recites the phrase 'establishing an a diagnosis of', where the word 'an' may be removed.

Claim 6 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. In the instant case claim 6 is drawn to a method for performing an assay to detect an alteration and 'if the results indicate the existence of an alteration in the SCN1A gene', performing one or more assays to identify the nature of the alteration. Claim 6 depends from claim 5, which is also drawn to a method comprising performing an assay to detect an alteration and to

identify the nature of the alteration. Thus claim 6 does not offer any further limitation to the subject matter of claim 5, and appears in some respects broader than claim 5.

***Claim Rejections - 35 USC § 112 2<sup>nd</sup> ¶ - Indefiniteness***

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 1-17, 20, and 21 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-3, 5-17, and 20 are unclear over recitation of the phrase 'detecting an alteration in the SCN1A gene', as recited in claim 1, because it is unclear what applicant intends for the phrase to encompass and thus the metes and bounds of the claimed subject matter are not clearly defined. It is unclear to what any patient's SCN1A gene would be compared in order to detect 'an alteration'. For example, many polymorphic and mutant forms of the SCN1A gene are known in the art, thus it is unclear if detecting such a polymorphic or mutant form of the gene in a patient would not be considered 'an alteration' as compared to any of these known forms. Neither the claims nor the specification set forth any standard to which a patient SCN1A gene may be compared to identify 'an alteration'.

Claims 1-17 and 20 are unclear because while the preamble of claim 1 (from which claims 2-17 and 20 depend) indicates a method for the diagnosis of SMEI in a patient, there is no final step in which SMEI is actually diagnosed in a patient, thus there

is not a clear correlation between the claimed steps of the method and accomplishing the purpose of the method as stated in the preamble. Claim 1 recites only diagnosis of a high probability of SMEI or a low probability of SMEI, so it is unclear how such a diagnosis of a probability of SMEI relates to actually diagnosing SMEI in a patient.

Claims 1-17 and 20 are unclear over recitation of the phrases 'high probability' and 'low probability' as recited in claim 1. While the unclear phrases indicate relative probabilities (i.e. 'high' or 'low') it is not clear to what the probabilities are being compared. It is thus unclear if applicant intends, for example, for 'a high probability' to mean some specific probability, or a probability higher than some specific probability.

Claims 1-17 and 20 are unclear over recitation of the phrase 'known to be' in reference to whether a detected alteration is SMEI associated or non-SMEI associated. It is not clear from either the claim or specification what is required, for example, for any particular mutation to be 'known to be SMEI associated'. For example, does an alteration 'known to be associated with SMEI' require that the mutation is associated with SMEI at some particular level of statistical significance, or known by a specific group of researchers to be associated with SMEI, or published in a certain publication as 'associated with SMEI'.

Claim 2 is unclear over recitation of the phrase 'a major disruption to the protein' as it is not clear if Applicant intends to claim a method requiring the detection of any particular alteration to the SCN1A gene. Neither the claim nor the specification nor the prior art offer a clear definition of what is considered 'a major disruption'.

Claims 2 and 3 are unclear over recitation of the phrase 'the protein' in claim 2 as there is no antecedent basis for any protein, thus it is unclear to what specific 'protein' the claim is referring.

Claims 2 and 3 are unclear over recitation of the phrase 'very high probability' as recited in claim 2. While the unclear phrase indicates a relative probability it is not clear to what the probability is being compared. It is thus unclear if applicant intends, for example, for 'a very high probability' to mean some specific probability, or a probability that is by some particular amount higher than some specific probability.

Claim 4 is unclear over recitation of the requirement 'wherein the alteration is one identified in Table 3', where, consonant with the election, Applicant has elected the missense mutation corresponding to the c251A→G nucleotide change. However, the phrase as written in the claim is unclear if the claim requires, for example, detection of a G at a particular position, or detection of a cysteine-encoding codon at a particular position. Because Table 3 includes a variety of information about each alteration, it is not clear what features provided in Table 3 are required to meet the limitations of the claims.

Claim 11 is unclear over recitation of the phrase 'the sample DNA' as there is not antecedent basis for any sample DNA.

Claims 21 is unclear because while the preamble of the claim indicates a method for the diagnosis of SMEI in a patient, there is no final step in which SMEI is actually diagnosed in a patient, thus there is not a clear correlation between the claimed steps of the method and accomplishing the purpose of the method as stated in the preamble.

Claim 21 recites only diagnosis of a high probability of SMEI or a low probability of SMEI, so it is unclear how such a diagnosis of a probability of SMEI relates to actually diagnosing SMEI in a patient.

Claim 21 is unclear over recitation of the phrases 'high probability' and 'low probability'. While the unclear phrases indicate relative probabilities (i.e. 'high' or 'low') it is not clear to what the probabilities are being compared. It is thus unclear if applicant intends, for example, for 'a high probability' to mean some specific probability, or a probability higher than some specific probability.

Claim 21 is unclear over recitation of the phrase 'alteration as laid out in Table 3', where, consonant with the election, Applicant has elected the missense mutation corresponding to the c251A→G nucleotide change. However, the phrase as written in the claim is unclear if the claim requires, for example, detection of a G at a particular position, or detection of a cysteine-encoding codon at a particular position. Because Table 3 includes a variety of information about each alteration, it is not clear what features provided in Table 3 are required to meet the limitations of the claims.

Claim 21 is unclear over recitation of the phrase 'known to be' in reference to whether a detected alteration is SMEI associated or non-SMEI associated. It is not clear from either the claim or specification what is required, for example, for any particular mutation to be 'known to be SMEI associated'. For example, does an alteration 'known to be associated with SMEI' require that the mutation is associated with SMEI at some particular level of statistical significance, or know by a specific group

of researchers to be associated with SMEI, or published in a certain publication as 'associated with SMEI'.

***Claim Rejections - 35 USC § 112 1<sup>st</sup>¶ - Written Description***

9. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

10. Claims 1-17, 20, and 21 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

It is noted that this rejection of method claims is made over the lack of an adequate written description of the broadly claimed methods encompassing the detection of any alteration in the SCN1A gene in a patient and making a diagnosis by detecting the alteration. In the instant case, the mutations are a critical element of the claimed method and therefore must be adequately described.

Applicant is referred to the guidelines on written description published January 5, 2001 in the Federal Register, Volume 66, Number 5, page 1099-111 (also available at [www.uspto.gov](http://www.uspto.gov)).

The claims of the instant application are drawn to methods of diagnosing SMEI in a patient requiring the detection of an alteration in the SCN1A gene. The methods of the claims encompass detecting any alteration in any portion of the SCN1A gene.

Claims 4 and 21, consonant with Applicants' Election, are drawn to methods requiring the detection of an alteration in the SCN1A gene identified as 'the missense mutation corresponding to the c251A→G nucleotide change'.

With specific regard to the limitations of claims 4 and 21, which, consonant with Applicants' Election, require the detection of an alteration that is described in Table 3 as a c251A→G nucleotide change, the art with regard to the numbering of nucleotides in the SCN1A gene indicate that there are different numbering systems applicable to the SCN1A gene. First, it is noted that while Table 3 indicates a nucleotide change at position 251 in which a G is substituted for an A and further specifies that this mutation is shown in SEQ ID NO: 1, the altered position with the G content in SEQ ID NO: 1 is at position 517 of SEQ ID NO: 1. Furthermore, within the art of the SCN1A gene sequence, the altered position is at position 269 in GenBank Locus AF2258985 and GenBank Locus NM\_006920 (see provided sequences). Thus an adequately specific written description is not provided for a method encompassing the identification of a 'c251A→G' mutation. This portion of the rejection may be overcome by more specifically identifying the nature of the identified mutation as a G at position 517 of SEQ ID NO: 1, as consonant with the Election.

When the claims are analyzed in light of the specification, the instant invention encompasses methods comprising the detection of an enormous number of alterations in the SCN1A gene. The specification teaches (p.6 ln.9):

The nature of the alterations in the SCN1A gene may encompass all forms of gene mutations including deletions, insertions, rearrangements and point mutations in the coding and non-coding regions such as the promoter, introns or untranslated regions. Deletions may be of the entire

gene or only a portion of the gene whereas point mutations may result in stop codons, frameshifts or amino acid substitutions. Point mutations occurring in the regulatory regions of SCN1A, such as in the promoter, may lead to loss or a decrease of expression of the mRNA or may abolish proper mRNA processing leading to a decrease in mRNA stability or translation efficiency.

Thus the claims encompass methods comprising the detection of any alteration anywhere in the SCN1A gene and further require ascertaining whether the alteration is 'known to be SMEI associated or non-SMEI associated'. However, the specification does not teach methods comprising the detection and analysis of nucleic acid sequences comprising SCN1A alterations of such a large genus as encompassed by the claims.

In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. The specification provides only methods comprising the detection and analysis of the 30 specific mutations of Table 3, and an SCN1A sequence that contains each particular mutation in SEQ ID NO: 1-25, and 49-53. The instant specification does not teach any methods comprising the analysis of any other particular alterations in the SCN1A gene. The specification further provides (Table 3, footnote 4) that a c677C→T mutation was found in a patient diagnosed with SMEI, and also seen in an individual that was not clinically diagnosed with SMEI.

Next, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics (e.g. other than nucleotide sequence or position within a particular gene), specific features

and functional attributes that would distinguish different members of the claimed genus. In the instant case, while the specification asserts one may make a diagnosis of 'high probability of SMEI' or 'low probability of SMEI' by ascertaining that a detected mutation is 'SMEI associated' or 'non-SMEI-associated', respectively, the specification actually provides methods comprising only the detection of the 30 mutations disclosed in Table 3, and does not provide any teachings regarding what is required, for example, for any of the multitude of particular mutations encompassed by the breadth of the claim to be 'SMEI associated'. As demonstrated by the example of the c677C→T mutation, if a mutation is found in a SMEI patient and also in a patient not clinically diagnosed with SMEI, is such a mutation considered 'SMEI associated' or 'non-SMEI-associated'? Thus the teachings of the specification do not provide guidance as to how one would *a priori* identify an SCN1A mutation that is 'known to be SMEI associated or non-SMEI associated'.

Applicants' attention is directed to the decision in *In re Shokal*, 113 USPQ 283 (CCPA 1957) wherein is stated:

It appears to be well settled that a single species can rarely, if ever, afford sufficient support for a generic claim. *In re Soll*, 25 C.C.P.A. (Patents) 1309, 97 F.2d 623, 38 USPQ 189; *In re Wahlforss et al.*, 28 C.C.P.A. (Patents) 867, 117 F.2d 270, 48 USPQ 397. The decisions do not however fix any definite number of species which will establish completion of a generic invention and it seems evident therefrom that such number will vary, depending on the circumstances of particular cases. Thus, in the case of small genus such as the halogens, consisting of four species, a reduction to practice of three, or perhaps even two, might serve to complete the generic invention, while in the case of a genus comprising hundreds of species, a considerably larger number of reductions to practice would probably be necessary.

The specification of the instant application discloses methods comprising the detection of the several particular alterations in the SCN1A gene of patients known to be either SMEI-diagnosed or non-SMEI-diagnosed. However the disclosure of the particular methods does not constitute an adequate written description of the broadly claimed methods which require diagnosing SMEI based upon, for example, determining whether the detected alteration is 'known to be SMEI associated or non-SMEI associated' because the specification does not clearly establish, given the multitude of nucleic acid sequences encompassed by the claims, what is required for any particular alteration to be 'known to be SMEI associated or non-SMEI associated'. Similarly, given the numerous nucleic acid sequences that are considered the 'SCN1A gene' as encompassed by the claimed methods, the specification does not provide a description of what is required for the detection of any 'alteration' in the SCN1A gene. Thus one of skill in the art cannot envision the detailed chemical structure of the sequences encompassed by the claimed methods, regardless of the complexity or simplicity of the method of detection. Adequate written description requires more than a statement that methods comprising the detection of sequence variants or 'alterations' within a particular region of a genome or with some particular association (e.g. 'known to be SMEI associated) are part of the invention and reference to a potential method for their identification. The particular nucleic acid sequences are themselves required.

In conclusion, the limited information provided regarding particular mutations as provided in the instant specification is not deemed sufficient to reasonably convey to one skilled in the art that Applicant is in possession of the broadly claimed nucleic acids encompassed by the claimed methods. Thus, having considered the breadth of the claims and the provisions of the specification, it is concluded that the specification does not provide adequate written description for the claims.

***Claim Rejections - 35 USC § 112 1<sup>st</sup> ¶ - Enablement***

11. Claims 1-17, 20, and 21 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

**Nature of the invention and breadth of the claims**

The claims of the instant application are drawn to methods for the diagnosis of SMEI in a patient.

The claims encompass the detection of any alteration anywhere in the SCN1A gene of a patient and making a diagnosis if the detected mutation is known to be SMEI associated or non-SMEI associated.

Claims 4 and 21, consonant with the Election, are drawn to the detection of the nucleotide change c251A→G.

The claims further encompass the diagnosis of a low probability of SMEI if the detected alteration is an inherited mutation, and a diagnosis of a high probability of SMEI if the detected alteration is a de novo mutation in the patient.

The claims encompass any subject organism, including any non-human subjects.

The claims thus require knowledge of whether or not any particular detected mutation is known to be SMEI associated or non-SMEI associated, and further depend on the concept that any detected de novo mutation in the SCN1A gene is indicative of SMEI.

**Direction provided by the specification and working example**

The instant specification teaches the sequence analysis of the SCN1A gene in a study population of individuals that had been diagnosed with SMEI from a clinical analysis or had severe encephalopathies occurring during the first 12 months of life (Example 1, p.38 Ins.1-5). The specification teaches the results of analysis of the 26 exons of the SCN1A gene in a total of 96 patients with the clinical epilepsy phenotype of the patients being hidden during the analysis. The specification further teaches that of the 96 patient samples analyzed, 34 samples were shown to have an alteration in the SCN1A gene, and of those 34 samples, 28 samples were from patients with a clear SMEI phenotype based on a clinical analysis (p.41 Ins.24-36).

The specification uses the above data from the example to draw the conclusion that 'if an SCN1A alteration is found in a patient, then the patient has an 82% chance (28/34) of having SMEI. However, this conclusion is based only

on the analysis of encephalopathic patients. There is no analysis of any general population to indicate that SCNA1 alterations of any kind in any portion of the gene (as is encompassed by the scope of the claims) occur with any particular frequency.

The specification provides no analysis of the SCN1A gene in any non-encephalopathic controls.

The specification provides no analysis of any non-human patients.

Insofar as the claims may encompass the analysis of the SCN1A protein for the detection alterations in the SCN1A gene, it is relevant to point out that the specification provides no examples of any methods in which the SCN1A protein is analyzed. The specification indicates that immunoassays for the SCN1A gene product are not currently known (p.12 Ins.11-12).

#### **State of the art, level of skill in the art, and level of unpredictability**

While the state of the art and level of skill in the art with regard to the detection of an alteration in any particular known gene sequence is high, the unpredictability of drawing an association between any gene mutation and a particular phenotype for diagnostic purposes is even higher. The unpredictability is demonstrated by the prior art, the post filing art, and the instant specification.

The unpredictability with regard to ascertaining whether a mutation is 'known to be SMEI associated' is demonstrated by the instant specification. For example, Table 3 of the specification indicates that a c677C→T mutation was found in a patient diagnosed with SMEI, and also seen in an individual that was not clinically diagnosed

with SMEI. Thus it is unpredictable as to what would be required for any particular mutation to be considered 'known to be SMEI associated'. It is not predictable if one of skill in the art would consider finding a particular mutation in one particular patient with SMEI evidence that the mutation is 'known to be SMEI associated'. With particular regard to the elected nucleotide change c251A→G, is the finding of this mutation in one SMEI patient in an encephalopathic population sufficient to indicate that this mutation is 'known to be SMEI associated'. The post filing art of Lucentini (2004) teaches that it is strikingly common for follow-up studies to find gene-disease associations wrong (left column, 3rd paragraph). Lucentini teaches that two recent studies found that typically when a finding is first published linking a given gene to a disease there is only roughly a one-third chance that the study will reliably confirm the finding (left column, 3rd paragraph). Lucentini teaches that bigger sample sizes and more family-based studies, along with revising statistical methods, should be included in the gene association studies (middle column, 1st complete paragraph).

Furthermore, with regard to the diagnosis of a patient based on establishing whether an identified mutation is an inherited or de novo mutation, the specification does not provide any analysis to indicate a significant association between, for example, the presence of a de novo mutation and the SMEI phenotype. GeneCard output indicates that there are 345 polymorphic variants of the SCN1A gene (GeneCard output page 6), thus it is clear that there are a multitude of alterations in the SCN1A gene (e.g. silent mutations, mutations in introns, missense mutations that do not effect the function of the encoded protein) that, even if they are de novo (i.e. not inherited from a parent),

would not be indicative of a diagnosis of SMEI in a patient. Similarly, the art of Fukuma et al (2004) teaches the identification seven mutations in the SCN1A gene that are present in SMEB patients (Table 1), which is a diagnosis distinct from SMEI (p.141 – Patients). This fact is also demonstrated by the data of Table 3 the instant specification, which provides five SCN1A gene mutations, including 2 truncation mutations, that are not associated with SMEI. Additionally, the specification provides no data regarding the de novo detection of SCN1A alterations in a non-encephalopathic population. The prior art of Thisted (1998) provides guidance as to what is required to indicate that an association is statistically significant (Thisted teaches that it has become scientific convention to say that a P-value of 0.05 is considered significant (p.5 - What does it mean to be 'statistically significant'), and that values above the conventional reference point of 0.05 would not be considered strong enough for the basis of a conclusion). It is thus unpredictable as to whether or not one can reliably diagnose a patient as having SMEI merely by identification of a de novo mutation. This is exemplified by the post-filing art of Kimura et al (2005), which teaches the presence of an SCN1A mutation in two related SMEI patients where the mutation was inherited from their father (Fig 1).

It is further relevant to point out that the example of the instant specification analyzes only an encephalopathic population, and does not provide any control population of random selected individuals. This is particularly relevant considering the teachings of Mulley et al (as cited in the IDS) which indicates that a significant number of SMEI cases have a family history of GEFS+ (p.173 – SCN1A mutations in SMEI). The reference further suggests that GEFS+ genes may interact with modifier genes

elsewhere in the genome to account for cases of SMEI diagnosed in families with GEFS+. It is thus unpredictable as to whether or not finding any particular specific mutation in one SMEI patient would thus make that mutation 'known to be associated with SMEI', and whether or not finding the mutation in any individual would in fact be indicative of a diagnosis of SMEI.

Regarding the required limitations of claim 11, it is not predictably established by either the instant specification or the prior art that detecting a length difference in an SCN1A exon amplified from a patient sample as compared to a wild-type SCN1A gene is specifically indicative of a truncation mutation. The specification indicates (p.6 lns. 24-25) that truncation mutations are those mutations such as frameshift mutations and nonsense mutations that lead to a truncated protein by creating an mRNA the translation of which is terminated prior to that of the non-mutated gene transcript. However, the art of Fukuma et al (2004) teaches that there are SCN1A mutations which would alter the size of the amplified exon, but not result in a truncation mutation and not be found in an SMEI patient (for example the F1756del mutation indicated in Table 1 and Fig 2C).

Additionally it is noted that the art of Sugawara et al (2003) teaches that SMEI associated mutations in the SCN1A gene result in functional differences in the encoded protein. However, even given the known structure of the SCN1A protein, neither the art nor the teachings of the instant specification teach how one may a priori identify a mutation in the SCN1A gene that is associated with SMEI or will effect the functionality of the resulting protein. Such unpredictability is demonstrated by the instant

specification, where in Table 3, several mutations, including truncating mutations, are indicated as non-SMEI associated.

Insofar as the claims may encompass the analysis of the SCN1A protein for the detection alterations in the SCN1A gene, it is relevant to point out that while the specification contemplates the development of mutant specific antibodies, the specification provides no examples of the detection of particular amino acid content in a polypeptide. The specification does not teach that it is in fact possible to differentiate between, for example, a tyrosine and a cysteine at amino acid 84 of SEQ ID NO: 26 (as consonant with the Election), or any particular SCN1A mutation, using a particular antibody, nor does the specification teach any particular antibody that is specific for this mutation. It is unpredictable whether any particular mutant form of the SCN1A protein would be sufficient to result in the production of antibodies that can differentiate between different molecules. In some cases, an antibody elicited by one antigen can cross-react with a different antigen if the two different antigens share an identical or very similar epitope (Goldsby et al., 2003, p. 141). Furthermore, the art teaches the unpredictability with regard to using an antibody to analyze a protein at the single amino acid level of specificity. DePalma teaches that, in contrast to gene hybridization techniques, antibody-protein interactions vary greatly and suffer from unpredictable cross-reactivity, and that antibodies are difficult to make (page 4, third full paragraph). It is thus unpredictable as to whether or not methods based on the analysis of the SCN1A protein would be suitable for the detection of particular mutations in the SCN1A gene.

Given the lack of data in the specification or the art regarding the effect of mutations in the SCN1A gene of non-human subjects on the diagnosis of the SMEI phenotype, it is unpredictable as to how one might extrapolate the data of the instant specification to any non-human animal.

#### **Quantity of experimentation required**

A large amount of experimentation would be required to make and use the claimed invention. In order to use the claimed method one would have to determine that any detected alteration is 'known to be SMEI associated or non-SMEI associated'. However the specification provides no guidance as to what is required to ascertain whether any detected alteration is, for example, 'known to be SMEI associated'. Given, for example, the data presented in the instant specification, where a mutation is found in an SMEI patient as well as a non-SMEI patient, one would have to establish that any mutation is in fact 'SMEI associated'. Furthermore, regarding establishing a diagnosis of SMEI based on the presence of an alteration not known to be either SMEI associated or non-SMEI associated where the mutation is a de novo mutation, given the extremely large number of alterations to the gene encompassed by the claims, one would have to establish that in fact any newly identified de novo mutation is associated with SMEI in a significant fashion, and thus indicative of a particular diagnosis.

#### **Conclusion**

Taking into consideration the factors outlined above, including the nature of the invention and breadth of the claims, the state of the art, the level of skill in the art and its high level of unpredictability, the guidance of the specification and the specific working

examples, it is the conclusion that an undue amount of experimentation would be required to make and use the claimed invention.

***Claim Rejections - 35 USC § 102***

The Examiner has rejected the claims of the instant application for a lack of enablement under 35 USC 112 1<sup>st</sup> ¶. The claims are also rejected under 35 USC 102 as anticipated by the cited reference. It is noted that the applied reference provides the same data as the instant specification, thus if the Applicant considers the instant specification enabling for the claims, the applied reference is similarly enabled.

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

13. Claims 1-3, 5-10, 12, 16, and 20 are rejected under 35 U.S.C. 102(b) as being anticipated by Claes et al (2001).

Claes et al teaches the analysis of mutations in the SCN1A gene and the relation of the mutations to SMEI.

Regarding claim 1, Claes et al teaches the detection of alterations in the SCN1A gene (Table 2), as required by step (1). Given that the mutations were first described by the work presented in the reference, relevant to step (3)(d), at the time of their discovery the mutations were not known to be either SMEI associated or non-SMEI associated, and relevant to step (3)(d) (i) and (ii) the reference teaches (p.1329, right col., last ¶) determining whether mutations were present in either of the unaffected parents (thus considering genetic data for parents, relevant to step (i)), and determining

that a mutation was absent from the parents (thus establishing that the mutation has arisen de novo). Relevant to step (3)(d)(iii), the reference teaches the analysis of subjects diagnosed with SMEI (p.1327 – Subjects), thus providing a diagnosis of SMEI and an asserted association between the identified SCN1A mutations and the phenotype, and further asserts that de novo mutations in SCN1A are probably a major cause of SMEI (p.1330 – Discussion).

Regarding claims 2 and 3, Claes et al teaches the identification of frameshift mutations that create premature stop codons (Table 2), which is establishing that the detected alteration is a truncation mutation that would result in a major disruption to the protein.

Regarding claims 5 and 6, Claes et al teaches performing an assay to detect a mutation (DHPLC), and further analysis to determine the nature of the mutation (sequence analysis) (p.1328 – Mutation detection and molecular-genetic analysis).

Regarding claims 7, 9, 10, 16 and 20, the reference teaches the analysis of SCN1A mutations using DHPLC and BigDye terminator-based sequencing, which are assays that encompass DNA hybridization (relevant to claim 7), high performance liquid chromatography (relevant to claim 9), electrophoresis (relevant to claim 10), the use of enzymes (relevant to claim 16), and DNA sequencing (relevant to claim 20).

Regarding claims 8 and 12, the reference teaches the amplification of genomic DNA from patients using oligonucleotide primers (Table 1), where such primers are SCN1A gene probes and oligonucleotides, and because of the specific nature of an DNA:DNA hybridization, such primers are allele specific probes at least insofar as they

specifically hybridize to nucleic acid containing the sequence of a cognate primer binding site.

***Claim Rejections - 35 USC § 103***

14. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

15. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

16. Claims 11, 13-15, and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Claes et al (2001) in view of Wong et al (2001, US Patent 6,331,614).

Claes et al teaches the detection of alterations in the SCN1A gene (Table 2), as required by step (1) of claim 1. Given that the mutations were first described by the work presented in the reference, relevant to step (3)(d) of claim 1, at the time of their discovery the mutations were not known to be either SMEI associated or non-SMEI associated, and relevant to step (3)(d) (i) and (ii) of claim 1 the reference teaches (p.1329, right col., last ¶) determining whether mutations were present in either of the unaffected parents (thus considering genetic data for parents, relevant to step (i)), and

determining that a mutation was absent from the parents (thus establishing that the mutation has arisen de novo). Relevant to step (3)(d)(iii) of claim 1, the reference teaches the analysis of subjects diagnosed with SMEI (p.1327 – Subjects), thus providing a diagnosis of SMEI and an asserted association between the identified SCN1A mutations and the phenotype, and further asserts that de novo mutations in SCN1A are probably a major cause of SMEI (p.1330 – Discussion). Relevant to claim 5, Claes et al teaches, Claes et al teaches performing an assay to detect a mutation (DHPLC), and further analysis to determine the nature of the mutation (sequence analysis) (p.1328 – Mutation detection and molecular-genetic analysis). Relevant to claim 16, the reference teaches the analysis of SCN1A mutations using amplification and sequencing of SCN1A exons, which are assays that use enzymes. Thus Claes et al teaches the required limitations of claims 1, 5, and 16, from which the rejected claims depend.

Claes et al does not specifically teach methods detecting alterations in gene sequences including the required limitations of the rejected claims.

Wong et al teaches a variety of methods for the analysis of alterations in gene sequences.

Regarding claim 11, Wong et al teaches methods in which alteration in a gene sequence is detected by determining the size of an amplification product, where a faster migrating sample is indicative of an alteration (col.42 Ins.25-37).

Regarding claims 13, 14, and 15, Wong et al teaches that various methods assay may be used to test for the existence of an alteration in a gene sequence, including

SSCP (e.g. col.37 ln.39) relevant to claim 13, RNase protection (e.g. col.5 ln.28) relevant to claim 14, and DGGE (e.g. col.6 ln.41). Regarding claim 17, Wong further teaches assay methods comprising the use of mutS (e.g. col.7 ln.8).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have used any assay technique known in the art for the detection of the SCN1A alterations associated with SMEI as taught by Claes et al. One would have been motivated to use any additional techniques, including the assay methods taught by Wong et.al, to have alternative methods for alteration detection comprising the use of different available reagents.

### ***Conclusion***

No claim is allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Kapushoc whose telephone number is 571-272-3312. The examiner can normally be reached on Monday through Friday, from 8am until 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached at 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Stephen Kapushoc  
Art Unit 1634



DIANA JOHANNSEN  
PRIMARY EXAMINER